- Home
- AAMI vs BLFS Comparison
AAMI vs BLFS Comparison
Compare AAMI & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- BLFS
- Stock Information
- Founded
- AAMI 1980
- BLFS 1987
- Country
- AAMI United States
- BLFS United States
- Employees
- AAMI N/A
- BLFS N/A
- Industry
- AAMI Investment Managers
- BLFS Medical/Dental Instruments
- Sector
- AAMI Finance
- BLFS Health Care
- Exchange
- AAMI Nasdaq
- BLFS Nasdaq
- Market Cap
- AAMI 1.1B
- BLFS 1.0B
- IPO Year
- AAMI N/A
- BLFS 1989
- Fundamental
- Price
- AAMI $38.79
- BLFS $20.78
- Analyst Decision
- AAMI Hold
- BLFS Strong Buy
- Analyst Count
- AAMI 3
- BLFS 7
- Target Price
- AAMI $30.33
- BLFS $30.57
- AVG Volume (30 Days)
- AAMI 282.3K
- BLFS 522.1K
- Earning Date
- AAMI 07-31-2025
- BLFS 08-07-2025
- Dividend Yield
- AAMI 0.10%
- BLFS N/A
- EPS Growth
- AAMI 46.05
- BLFS N/A
- EPS
- AAMI 2.40
- BLFS N/A
- Revenue
- AAMI $519,799,999.00
- BLFS $87,762,000.00
- Revenue This Year
- AAMI $5.28
- BLFS $21.21
- Revenue Next Year
- AAMI $6.24
- BLFS $17.58
- P/E Ratio
- AAMI $16.18
- BLFS N/A
- Revenue Growth
- AAMI 18.00
- BLFS 34.80
- 52 Week Low
- AAMI $21.49
- BLFS $19.10
- 52 Week High
- AAMI $39.85
- BLFS $29.55
- Technical
- Relative Strength Index (RSI)
- AAMI N/A
- BLFS 40.13
- Support Level
- AAMI N/A
- BLFS $21.91
- Resistance Level
- AAMI N/A
- BLFS $23.25
- Average True Range (ATR)
- AAMI 0.00
- BLFS 0.94
- MACD
- AAMI 0.00
- BLFS -0.04
- Stochastic Oscillator
- AAMI 0.00
- BLFS 3.94
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.